Rais K. Khayretdinov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Rais K. Khayretdinov has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Igor' Leonidovich Davydkin
Samara State Medical University
4 shared publications - Olesya Evgen'EVna Danilova
Samara State Medical University, Ministry of Health of Russia
4 shared publications - I. L. Davydkin
Samara State Medical University
3 shared publications - Владимир Петрович Кузьмин
Samara State Medical University
3 shared publications - Светлана Петровна Кривова
Samara State Medical University
3 shared publications - G. R. Gimatdinova
Samara State Medical University
2 shared publications
Latest Publications
- Open Access
- 5 May 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (2) , 127-135
QTC INTERVAL PROLONGATION: ROLE OF POLYPHARMACY, DRUG INTERACTION AND CONSIDERATIONS FOR CLINICAL PRACTICE
Highlights Acquired long QT syndrome is a rare disease, but the frequency of QTc prolongation increases with polypragmasia. AbstractAcquired long QT syndrome is a rare condition. However, the prevalence of prolonged QTc interval increases among patients with polypharmacy. The risk of both QTc interval prolongation and torsades de pointes (TdP) tachycardia escalates exponentially with the concomitant use of multiple QTc-prolonging drugs. This article explores the underlying mechanisms of the condition and methods to mitigate the risk of potentially fatal arrhythmias.
- 5 May 2025
- Published by NII KPSSZ in Complex Issues of Cardiovascular Diseases
- Vol. 14 (2) , 127-135
Open AccessQTC INTERVAL PROLONGATION: ROLE OF POLYPHARMACY, DRUG INTERACTION AND CONSIDERATIONS FOR CLINICAL PRACTICE
Highlights Acquired long QT syndrome is a rare disease, but the frequency of QTc prolongation increases with polypragmasia. AbstractAcquired long QT syndrome is a rare condition. However, the prevalence of prolonged QTc interval increases among patients with polypharmacy. The risk of both QTc interval prolongation and torsades de pointes (TdP) tachycardia escalates exponentially with the concomitant use of multiple QTc-prolonging drugs. This article explores the underlying mechanisms of the condition and methods to mitigate the risk of potentially fatal arrhythmias.
- Open Access
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 169-175
Results of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease
Aim. To collect and analyze real-world data on long-term enzyme replacement therapy with Glurazyme® in patients with type I Gaucher disease (GD). Materials and methods. The study included 31 patients with type I GD (21 patients with intact spleen and 10 patients with a history of splenectomy) over 18 years. Efficacy was assessed by the change in hemoglobin level (primary endpoint), platelet count, spleen and liver volumes, prevalence of bone marrow infiltration, and the number of patients with quiet hip disease according to magnetic resonance imaging (secondary endpoints). Safety was assessed by the incidence of treatment-related adverse events and serious adverse events, as well as by the incidence of production of imiglucerase binding and neutralizing antibodies (IgG, IgE). The mean follow-up duration was 54 weeks. Results. The study did not show a statistically significant change in hemoglobin levels, platelet count, or spleen and liver volumes. There was an upward tendency in platelet count in the overall group (p=0.1) and patients after splenectomy (p=0.08). The prevalence of specific bone marrow infiltration and the number of patients with quiet hip disease remained unchanged. During the safety analysis, one adverse reaction, a mild increase in alanine aminotransferase, was reported, which resolved spontaneously by the end of the study. The immunogenicity analysis showed the initial presence of anti-drug antibodies (ADAs) in 5 (16.7%) of the 30 examined patients. At the end of the study, ADAs were detected in only 3 (10%) patients. The detected ADAs had a low titer and no neutralizing activity, and they did not affect the treatment effectiveness. Conclusion. Long-term therapy with the imiglucerase biosimilar was associated with a stable course of GD without progression. It was characterized by a good safety profile and low immunogenicity.
- 26 March 2025
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 97 (2) , 169-175
Open AccessResults of a prospective observational study of imiglucerase biosimilar in adults with type I Gaucher disease
Aim. To collect and analyze real-world data on long-term enzyme replacement therapy with Glurazyme® in patients with type I Gaucher disease (GD). Materials and methods. The study included 31 patients with type I GD (21 patients with intact spleen and 10 patients with a history of splenectomy) over 18 years. Efficacy was assessed by the change in hemoglobin level (primary endpoint), platelet count, spleen and liver volumes, prevalence of bone marrow infiltration, and the number of patients with quiet hip disease according to magnetic resonance imaging (secondary endpoints). Safety was assessed by the incidence of treatment-related adverse events and serious adverse events, as well as by the incidence of production of imiglucerase binding and neutralizing antibodies (IgG, IgE). The mean follow-up duration was 54 weeks. Results. The study did not show a statistically significant change in hemoglobin levels, platelet count, or spleen and liver volumes. There was an upward tendency in platelet count in the overall group (p=0.1) and patients after splenectomy (p=0.08). The prevalence of specific bone marrow infiltration and the number of patients with quiet hip disease remained unchanged. During the safety analysis, one adverse reaction, a mild increase in alanine aminotransferase, was reported, which resolved spontaneously by the end of the study. The immunogenicity analysis showed the initial presence of anti-drug antibodies (ADAs) in 5 (16.7%) of the 30 examined patients. At the end of the study, ADAs were detected in only 3 (10%) patients. The detected ADAs had a low titer and no neutralizing activity, and they did not affect the treatment effectiveness. Conclusion. Long-term therapy with the imiglucerase biosimilar was associated with a stable course of GD without progression. It was characterized by a good safety profile and low immunogenicity.
- Open Access
- 28 May 2024
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 114-121
Gender cardiology: clinical and pathophysiological features of the course the main diseases in women
Coronary heart disease is the leading cause of death for both women and men. Older women, when coronary heart disease first appears, have more comorbidities and usually complain of atypical symptoms. Mortality and hospitalization rates caused by acute myocardial infarction are higher for women. It should be noted that adherence to secondary prevention for women is lower.Female predominance has been noted in idiopathic pulmonary arterial hypertension (IPAH), hereditary pulmonary hypertension, and collagenosisassociated pulmonary arterial hypertension. However, according to the latest data of the European register COMPERA, gender differences disappear for elderly patients and for the patients having concomitant diseases. The more frequent occurrence of cardiomyopathies among women is considered. Peripartum cardiomyopathy associated with pregnancy and childbirth, and Takotsubo cardiomyopathy due to psychoemotional status, in particular a stressful situation, determines a woman's further prognosis. Arrythmias are explained by changes in hormonal status during pregnancy, menopause, or are associated with the onset of the underlying disease.Heart failure usually affects both sexes equally, with women more likely to suffer from HFpEF and men from HFrEF. The classic cardiovascular, gender, and social risk factors for cardiovascular disease and heart failure have a different meaning for women than for men. It is necessary to take into account the parameters for EchoCG diagnostics for women, since the size of the women heart is smaller.
- 28 May 2024
- Published by Intermedservice Ltd in Eurasian heart journal
- No. 2,p. 114-121
Open AccessGender cardiology: clinical and pathophysiological features of the course the main diseases in women
Coronary heart disease is the leading cause of death for both women and men. Older women, when coronary heart disease first appears, have more comorbidities and usually complain of atypical symptoms. Mortality and hospitalization rates caused by acute myocardial infarction are higher for women. It should be noted that adherence to secondary prevention for women is lower.Female predominance has been noted in idiopathic pulmonary arterial hypertension (IPAH), hereditary pulmonary hypertension, and collagenosisassociated pulmonary arterial hypertension. However, according to the latest data of the European register COMPERA, gender differences disappear for elderly patients and for the patients having concomitant diseases. The more frequent occurrence of cardiomyopathies among women is considered. Peripartum cardiomyopathy associated with pregnancy and childbirth, and Takotsubo cardiomyopathy due to psychoemotional status, in particular a stressful situation, determines a woman's further prognosis. Arrythmias are explained by changes in hormonal status during pregnancy, menopause, or are associated with the onset of the underlying disease.Heart failure usually affects both sexes equally, with women more likely to suffer from HFpEF and men from HFrEF. The classic cardiovascular, gender, and social risk factors for cardiovascular disease and heart failure have a different meaning for women than for men. It is necessary to take into account the parameters for EchoCG diagnostics for women, since the size of the women heart is smaller.
- Open Access
- 2 February 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (1S) , 5354
Oral anticoagulants or antiplatelet drugs after heart valve reconstructive surgery: modern guidelines for the practitioners
After heart valve surgery, anticoagulant therapy is usually recommended. The duration and necessity of combining oral anticoagulants with antiplatelet drugs depends on the type of manipulation performed, patient comorbidity and some other factors. Several randomized trials have shown that continued direct oral anticoagulation as monotherapy in some groups of patients requiring cardiac surgery is superior in efficacy and safety to treatment combining anticoagulant and antiplatelet drugs. The presented literature review reflects the management strategy of patients after heart valve operations.
- 2 February 2024
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 29 (1S) , 5354
Open AccessOral anticoagulants or antiplatelet drugs after heart valve reconstructive surgery: modern guidelines for the practitioners
After heart valve surgery, anticoagulant therapy is usually recommended. The duration and necessity of combining oral anticoagulants with antiplatelet drugs depends on the type of manipulation performed, patient comorbidity and some other factors. Several randomized trials have shown that continued direct oral anticoagulation as monotherapy in some groups of patients requiring cardiac surgery is superior in efficacy and safety to treatment combining anticoagulant and antiplatelet drugs. The presented literature review reflects the management strategy of patients after heart valve operations.
- Open Access
- 14 September 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (3S) , 5069
Genetic polymorphisms associated with the development of arrhythmic type of cardiovascular events
The review analyzes the global agenda on mutational status of genes associated with adverse cardiovascular events of arrhythmic type. Whole exome sequencing will identify a risk group for the likelihood of early or delayed cardiovascular events of arrhythmic type, especially among patients receiving anticancer therapy with cardiotoxic drugs. The dedicated up-to-date panel of genetic polymorphisms will provide an opportunity to optimize management of patients, based on not only clinical, paraclinical and anamnestic data.
- 14 September 2022
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 27 (3S) , 5069
Open AccessGenetic polymorphisms associated with the development of arrhythmic type of cardiovascular events
The review analyzes the global agenda on mutational status of genes associated with adverse cardiovascular events of arrhythmic type. Whole exome sequencing will identify a risk group for the likelihood of early or delayed cardiovascular events of arrhythmic type, especially among patients receiving anticancer therapy with cardiotoxic drugs. The dedicated up-to-date panel of genetic polymorphisms will provide an opportunity to optimize management of patients, based on not only clinical, paraclinical and anamnestic data.
- 30 September 2020
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 9 (3)
Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy
The article is dedicated to contemporary views on the change of endothelial function in the patients with lymphoproliferative disorders prior to, and in the process of, chemotherapeutic treatment. Considering that possibilities of standard examination do not always help identifying subclinical endothelial dysfunction, it is necessary to use specific methods, in particular, to determine the levels of endothelin-1 and vascular endothelial growth factor to monitor endothelial function. The objective of this review is to identify problems and prospects for recognizing early subclinical changes of endothelial function in the patients with lymphoproliferative disorders before and after chemotherapy. Assessing presence and severity of endothelial dysfunction may be useful for determining subclinical stages of cardiovascular damage, stratifying the risk of the patients with confirmed cardiovascular disease, and reducing the likelihood of cardio- and endotheliotoxic effects in patients long after chemotherapy. That is why early detection and immediate therapy of cardiovascular toxicity is currently the most important task in the patients with lymphoproliferative disorders, receiving chemotherapy.
- 30 September 2020
- Published by LLC Science and Innovations in Russian Open Medical Journal
- Vol. 9 (3)
Endothelial dysfunction in patients with lymphoproliferative disorders and its changes in the course of polychemotherapy
The article is dedicated to contemporary views on the change of endothelial function in the patients with lymphoproliferative disorders prior to, and in the process of, chemotherapeutic treatment. Considering that possibilities of standard examination do not always help identifying subclinical endothelial dysfunction, it is necessary to use specific methods, in particular, to determine the levels of endothelin-1 and vascular endothelial growth factor to monitor endothelial function. The objective of this review is to identify problems and prospects for recognizing early subclinical changes of endothelial function in the patients with lymphoproliferative disorders before and after chemotherapy. Assessing presence and severity of endothelial dysfunction may be useful for determining subclinical stages of cardiovascular damage, stratifying the risk of the patients with confirmed cardiovascular disease, and reducing the likelihood of cardio- and endotheliotoxic effects in patients long after chemotherapy. That is why early detection and immediate therapy of cardiovascular toxicity is currently the most important task in the patients with lymphoproliferative disorders, receiving chemotherapy.
- Open Access
- 11 March 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (2) , 90-97
Myocardial contractility dysfunction in patients with chronic lymphocytic leukemia receiving chemotherapy and their treatment with enalapril
Aim. To assess eft ventricular (LV) contractility dysfunction in patients with chronic lymphocytic leukemia (CLL) receiving chemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), and to determine the enalapril.effectiveness for their treatment.Material and methods. The study included 49 patients with newly diagnosed Binet stage B CLL in combination with class I-II stable angina, stage 1-2 hypertension and LV ejection fraction (EF) >50%. All subjects did not take angiotensin converting enzyme inhibitors (ACE inhibitors), had no clinical signs of heart failure (HF), and all had indications for FCR combination use before study start. Patients underwent two-dimensional echocardiography initially, before starting chemotherapy (period V1) and after three (84±5 days) (V2) and six (168±7 days) (V3) courses of chemo therapy (enalapril) was added to the treatment regimen in the experimental group.Results. After the third course of chemotherapy, a relative percentage decrease in global longitudinal strain (GLS) was noted in the experimental and control groups — by 16,16±0,80 and 16,2±0,79, respectively (p=0,764). These changes are considered a cardiotoxicity predictor. At the same time, LVEF values remained within the normal range: 63,4% [65; 68] in the experimental group and 63,9% [61,6; 67] in the control group (p=0,960). After the sixth course, LVEF values significantly differed (p=0,002): in the control group, five patients (21%) had cardiotoxicity; in experimental group, there were no patients with cardiotoxicity.Conclusion. A clinically significant decrease in GLS is a marker of subclinical LV contractile dysfunction and is a cardiotoxicity predictor in CLL patients receiving chemotherapy with FCR. The timely addition of enalapril to the treatment regimen can prevent cardiotoxicity in such patients. The need for early assessment of GLS during FCR courses for the detection and prevention of cardiotoxicity has been proved.
- 11 March 2020
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 25 (2) , 90-97
Open AccessMyocardial contractility dysfunction in patients with chronic lymphocytic leukemia receiving chemotherapy and their treatment with enalapril
Aim. To assess eft ventricular (LV) contractility dysfunction in patients with chronic lymphocytic leukemia (CLL) receiving chemotherapy with fludarabine, cyclophosphamide, and rituximab (FCR), and to determine the enalapril.effectiveness for their treatment.Material and methods. The study included 49 patients with newly diagnosed Binet stage B CLL in combination with class I-II stable angina, stage 1-2 hypertension and LV ejection fraction (EF) >50%. All subjects did not take angiotensin converting enzyme inhibitors (ACE inhibitors), had no clinical signs of heart failure (HF), and all had indications for FCR combination use before study start. Patients underwent two-dimensional echocardiography initially, before starting chemotherapy (period V1) and after three (84±5 days) (V2) and six (168±7 days) (V3) courses of chemo therapy (enalapril) was added to the treatment regimen in the experimental group.Results. After the third course of chemotherapy, a relative percentage decrease in global longitudinal strain (GLS) was noted in the experimental and control groups — by 16,16±0,80 and 16,2±0,79, respectively (p=0,764). These changes are considered a cardiotoxicity predictor. At the same time, LVEF values remained within the normal range: 63,4% [65; 68] in the experimental group and 63,9% [61,6; 67] in the control group (p=0,960). After the sixth course, LVEF values significantly differed (p=0,002): in the control group, five patients (21%) had cardiotoxicity; in experimental group, there were no patients with cardiotoxicity.Conclusion. A clinically significant decrease in GLS is a marker of subclinical LV contractile dysfunction and is a cardiotoxicity predictor in CLL patients receiving chemotherapy with FCR. The timely addition of enalapril to the treatment regimen can prevent cardiotoxicity in such patients. The need for early assessment of GLS during FCR courses for the detection and prevention of cardiotoxicity has been proved.